(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.69%) $83.27
(-1.16%) $1.619
(-0.02%) $2 346.70
(-0.07%) $27.52
(0.20%) $923.90
(-0.08%) $0.934
(0.00%) $11.02
(-0.12%) $0.799
(0.00%) $92.17
@ $26.12
発行日: 11 4月 2024 @ 04:05
リターン: -5.51%
前回のシグナル: 4月 10 - 02:08
前回のシグナル:
リターン: -2.68 %
Live Chart Being Loaded With Signals
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally...
Stats | |
---|---|
本日の出来高 | 968 493 |
平均出来高 | 2.00M |
時価総額 | 4.12B |
EPS | $0 ( 2024-04-24 ) |
次の収益日 | ( $0 ) 2024-07-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 8.07 |
ATR14 | $0.0240 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Lurker Nancy | Buy | 22 103 | Non Qualified Stock Option (Right to Buy) |
2024-04-11 | Lurker Nancy | Buy | 11 255 | Restricted Stock Unit Award |
2024-04-11 | Lurker Nancy | Buy | 4 833 | Non Qualified Stock Option (Right to Buy) |
2024-04-11 | Lurker Nancy | Buy | 2 323 | Restricted Stock Unit Award |
2024-03-18 | Nichols Christian Todd | Sell | 10 417 | Ordinary Shares |
INSIDER POWER |
---|
75.16 |
Last 99 transactions |
Buy: 1 207 179 | Sell: 170 568 |
ボリューム 相関
Alkermes Plc 相関
10 最も負の相関 | |
---|---|
QADB | -0.914 |
WNEB | -0.905 |
EBACU | -0.899 |
MPRA | -0.898 |
PKOH | -0.898 |
DRNA | -0.898 |
JNCE | -0.895 |
MLAI | -0.892 |
SQQQ | -0.892 |
VS | -0.886 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Alkermes Plc 相関 - 通貨/商品
Alkermes Plc 財務諸表
Annual | 2023 |
収益: | $1.66B |
総利益: | $1.37B (82.64 %) |
EPS: | $2.14 |
FY | 2023 |
収益: | $1.66B |
総利益: | $1.37B (82.64 %) |
EPS: | $2.14 |
FY | 2022 |
収益: | $1.11B |
総利益: | $893.69M (80.38 %) |
EPS: | $-0.970 |
FY | 2021 |
収益: | $1.17B |
総利益: | $569.84M (48.55 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Alkermes Plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。